'After this, there are many options for Chinese citizens to be injected with what flavor vaccine.'
The easing of China's zero-Covid policy appears to be opening up space for German vaccination company BioNTech to enter the Great Wall market.
Most recently, the company confirmed that 11,500 doses of the BioNTech Covid-19 vaccine had safely landed in China to be given to German citizens living there.
The company's official statement revealed that the amount of vaccine was enough to give all or half of the 20,000 Germans living in China.
The vaccine sent is the type that has the original Covid-19 virus chain and the inactive Omicron BA.4/BA.5 sub-variants.
It also marks the first presence of foreign vaccines in the Chinese market after Xi Jinping's government previously only allowed the use of locally produced vaccines.
Commented BioNTech Chief Business and Commercial Officer, Sean Marett, it is a historic moment in China after the relaxation of their zero-Covid policy.
In addition, Marett also expressed his excitement to establish a closer partner relationship with China in dealing with the Covid-19 epidemic.
Generally, BioNTech cooperates with Shanghai Fosun Pharmaceutical in bringing the vaccine into China.
Meanwhile, the actual number of Covid cases in China is in doubt with British health data firm Airfinity based there estimating infections to exceed 1 million a day with nearly 5,000 deaths.
There are strong rumors that health officials and the Chinese government are hiding the true number of infection cases after the relaxation of the zero-Covid policy to ease concerns and protests that took place a few weeks ago.
